A Multicenter, Controlled, Open-label Extension (OLE) Study to Assess the Long-term Safety and Efficacy of AMG 145
A Multicenter, Controlled, Open-label Extension (OLE) Study to Assess the Long-term Safety and Efficacy of AMG 145
This study will contribute to the evaluation of long-term safety, tolerability and efficacy of evolocumab (AMG 145) in adults with hyperlipidemia and adults with mixed dyslipidemia.
Inclusion Criteria:
- Complete a qualifying evolocumab (AMG 145) parent study (ie, Study 20110114 [NCT01763827], 20110115 [NCT01763866], 20110116 [NCT01763905], 20110117 [NCT01763918], 20110109 [NCT01516879], 20120122 [NCT01953328], 20120332 [NCT01984424], 20120348 [NCT01849497], or 20120356 [NCT01879319]).
Exclusion Criteria:
Kitakyusyu-shi, Fukuoka 807-0856, Japan
Koriyama-shi, Fukushima 963-0209, Japan
Koriyama-shi, Fukushima 963-8026, Japan
Koriyama-shi, Fukushima 963-8041, Japan
Koriyama-shi, Fukushima 963-8832, Japan
Koriyama-shi, Fukushima 963-8862, Japan
Takasaki-shi, Gunma 370-3524, Japan
Tsuchiura-shi, Ibaraki 300-0047, Japan
Tomigusuku-shi, Okinawa 901-0243, Japan
Ibaraki-shi, Osaka 567-0876, Japan
Toyonaka-shi, Osaka 560-0082, Japan
Koshigaya-shi, Saitama 343-0828, Japan
Niiza-shi, Saitama 352-0014, Japan
Arakawa-ku, Tokyo 116-0002, Japan
Chiyoda-ku, Tokyo 101-0041, Japan
Chofu-shi, Tokyo 182-0006, Japan
Edogawa-ku, Tokyo 133-0061, Japan
Hachioji-shi, Tokyo 192-0046, Japan
Koto-ku, Tokyo 135-0011, Japan
Minato-ku, Tokyo 105-7390, Japan
Minato-ku, Tokyo 108-0075, Japan
Setagaya-ku, Tokyo 155-0031, Japan
Shibuya-ku, Tokyo 150-0012, Japan
Shinagawa-ku, Tokyo 140-0011, Japan
Shinagawa-ku, Tokyo 141-0001, Japan
Shinagawa-ku, Tokyo 141-6003, Japan
Shinagawa-ku, Tokyo 142-0053, Japan
Toshima-ku, Tokyo 171-0021, Japan
Muensterlingen, 8596, Switzerland